文献速递临床试验与 GCP流行病学与生物统计

INFERR-血液透析铁输注研究:对血清铁蛋白水平高的澳大利亚原住民血液透析患者静脉输注多糖铁的前瞻性开放标签盲法终点随机对照试验方案

INFERR-Iron infusion in haemodialysis study: INtravenous iron polymaltose for First Nations Australian patients with high FERRitin levels on haemodialysis-a protocol for a prospective open-label blinded endpoint randomised controlled trial.
PubMed 文献 · Trials · 2021-12-02

本研究为前瞻性开放标签盲法终点随机对照试验,计划在澳大利亚北领地7个肾脏中心纳入576例维持性血液透析、铁蛋白>700 μg/L且≤2000 μg/L、转铁蛋白饱和度<40%的原住民患者,1:1随机接受每月一次静脉多糖铁400 mg或不接受静脉铁治疗,主要比较两组全因感染住院或死亡风险差异。

要点

  • 研究针对铁蛋白高且转铁蛋白饱和度低的原住民血液透析患者,比较静脉铁与不补铁对感染住院或死亡的影响。
  • 干预组为静脉多糖铁400 mg每月一次(连续2次透析各200 mg),对照组不接受静脉铁治疗。
  • 主要结局为两组全因感染住院或死亡风险的差异,同时进行经济学分析及次要和三级结局分析。

核心结论

  • 该试验旨在评估静脉铁治疗对高铁蛋白、低转铁蛋白饱和度原住民血液透析患者全因死亡及全因感染住院的影响,以填补该人群铁治疗安全性和有效性的证据空白。

研究设计与样本

  • 前瞻性开放标签盲法终点随机对照试验,计划在澳大利亚北领地全部7个肾脏中心纳入576例维持性血液透析患者。
  • 纳入标准为铁蛋白>700 μg/L且≤2000 μg/L、转铁蛋白饱和度<40%的原住民患者,1:1随机分为静脉多糖铁组(A组)和不接受静脉铁治疗的标准化疗组(B组)。

主要发现

  • A组接受静脉多糖铁400 mg每月一次(连续2次血液透析各200 mg),B组不接受静脉铁治疗。
  • 当铁蛋白水平降至700 μg/L以下或临床有指征时给予补救治疗。
  • 主要结局为两组全因感染住院或死亡风险的差异,并计划进行经济学分析及多项次要和三级结局分析。

关键数值与推荐

  • 纳入铁蛋白>700 μg/L且≤2000 μg/L、转铁蛋白饱和度<40%的维持性血液透析患者。
  • 补救治疗指征为铁蛋白水平降至700 μg/L以下或临床有指征。

临床怎么用

  • 原文未据此给出临床推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: The effectiveness of erythropoiesis-stimulating agents, which are the main stay of managing anaemia of chronic kidney disease (CKD), is largely dependent on adequate body iron stores. The iron stores are determined by the levels of serum ferritin concentration and transferrin saturation. These two surrogate markers of iron stores are used to guide iron replacement therapy. Most Aboriginal and/or Torres Islander Australians of the Northern Territory (herein respectfully referred to as First Nations Australians) with end-stage kidney disease have ferritin levels higher than current guideline recommendations for iron therapy. There is no clear evidence to guide safe and effective treatment with iron in these patients. We aim to assess the impact of intravenous iron treatment on all-cause death and hospitalisation with a principal diagnosis of all-cause infection in First Nations patients on haemodialysis with anaemia, high ferritin levels and low transferrin saturation METHODS: In a prospective open-label blinded endpoint randomised controlled trial, a total of 576 participants on maintenance haemodialysis with high ferritin (> 700 μg/L and ≤ 2000 μg/L) and low transferrin saturation (< 40%) from all the 7 renal units across the Northern Territory of Australia will be randomised 1:1 to receive intravenous iron polymaltose 400 mg once monthly (200 mg during 2 consecutive haemodialysis sessions) (Arm A) or no IV iron treatment (standard treatment) (Arm B). Rescue therapy will be administered when the ferritin levels fall below 700 μg/L or when clinically indicated. The primary outcome will be the differences between the two study arms in the risk of hospitalisation with all-cause infection or death. An economic analysis and several secondary and tertiary outcomes analyses will also be performed. DISCUSSION: The INFERR clinical trial will address significant uncertainty on the safety and efficacy of iron therapy in First Nations Australians with CKD with hyperferritinaemia and evidence of iron deficiency. This will hopefully lead to the development of evidence-based guidelines. It will also provide the opportunity to explore the causes of hyperferritinaemia in First Nations Australians from the Northern Territory. TRIAL REGISTRATION: This trial is registered with The Australian New Zealand Clinical Trials Registry (ANZCTR): ACTRN12620000705987 . Registered 29 June 2020.

来源:Trials,查看原文。版权归原作者所有。

引用

  1. Majoni SW, Nelson J, Germaine D, et al. INFERR-Iron infusion in haemodialysis study: INtravenous iron polymaltose for First Nations Australian patients with high FERRitin levels on haemodialysis-a protocol for a prospective open-label blinded endpoint randomised controlled trial. Trials. 2021. PMID: 34857020. doi:10.1186/s13063-021-05854-w

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。